¼¼°èÀÇ Å¬¸®´ÏÄà ÀÎÅÚ¸®Àü½º ½ÃÀå
Clinical Intelligence
»óǰÄÚµå : 1798373
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 213 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,209,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,629,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Å¬¸®´ÏÄà ÀÎÅÚ¸®Àü½º ½ÃÀåÀº 2030³â±îÁö 36¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 14.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 36¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¼ÒÇÁÆ®¿þ¾î ÄÄÆ÷³ÍÆ®´Â CAGR 16.5%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 24¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Çϵå¿þ¾î ÄÄÆ÷³ÍÆ® ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 11.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 4¾ï 880¸¸ ´Þ·¯, Áß±¹Àº CAGR 13.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Å¬¸®´ÏÄà ÀÎÅÚ¸®Àü½º ½ÃÀåÀº 2024³â¿¡ 4¾ï 880¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³â°£ CAGR13.8%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â¿¡´Â 5¾ï 4,800¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 13.8%¿Í 12.6%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 10.6%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Å¬¸®´ÏÄà ÀÎÅÚ¸®Àü½º ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º°¡ Àü ¼¼°è ÇコÄɾî ÀÇ»ç°áÁ¤À» ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º ¼¼°è ½ÃÀåÀº ±Þ°ÝÇÑ º¯È­¸¦ °ÞÀ¸¸ç ÁøÈ­ÇÏ´Â ÇコÄɾîÀÇ Áß¿äÇÑ ÃàÀ¸·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ µ¥ÀÌÅÍ °úÀ×, ȯÀÚ ¼ö Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ´Â °¡¿îµ¥, Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º´Â ¿ø½Ã µ¥ÀÌÅ͸¦ ½Ç¿ëÀûÀÎ ÅëÂû·ÂÀ¸·Î ÀüȯÇÏ´Â Áß¿äÇÑ µµ±¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ºòµ¥ÀÌÅÍ ºÐ¼®, ¸Ó½Å·¯´× ¾Ë°í¸®Áò, ÀÚ¿¬¾î ó¸®, ½Ç½Ã°£ ȯÀÚ µ¥ÀÌÅÍ ÅëÇÕ, ÀÓ»óÀû ÆÇ´Ü Áö¿ø, ȯÀÚ °á°ú °³¼±, ¾÷¹« ºñÈ¿À²¼º °¨¼Ò¸¦ ½ÇÇöÇÕ´Ï´Ù. ±× Àû¿ë ¹üÀ§´Â ¿¹Ãø ¸ðµ¨¸µ°ú À§Çè °èÃþÈ­, Áý´Ü °Ç°­ °ü¸® ¹× ÀÓ»ó ¿öÅ©Ç÷οì ÃÖÀûÈ­±îÁö È®ÀåµÇ°í ÀÖ½À´Ï´Ù. ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç µî °¢±¹ Á¤ºÎ¿Í º¸°Ç ±â°üÀº °¡Ä¡ ±â¹Ý ÀÇ·á ¼­ºñ½º Á¦°øÀ» °­È­Çϱâ À§ÇØ °ø°ø º¸°Ç ÀÌ´Ï¼ÅÆ¼ºê¿¡ Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º¸¦ ÅëÇÕÇÏ·Á´Â ¿òÁ÷ÀÓÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷, ÀüÀڰǰ­±â·Ï(EHR) ¹× »óÈ£¿î¿ë °¡´ÉÇÑ ½Ã½ºÅÛÀÇ º¸±ÞÀ¸·Î ÀÎÇÑ ÇコÄÉ¾î ±â·ÏÀÇ ±Þ¼ÓÇÑ µðÁöÅÐÈ­°¡ ±× äÅÃÀ» Å©°Ô °¡¼ÓÈ­Çϰí ÀÖ´Ù´Â Á¡À» ÁÖ¸ñÇÒ Çʿ䰡 ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ Á᫐ ¸ðµ¨À» °­Á¶Çϸ鼭 Áø´Ü°ú Ä¡·á °æ·Î »çÀÌÀÇ Á¤º¸ °ÝÂ÷¸¦ ÇØ¼ÒÇÒ ¼ö ÀÖ´Â °í±Þ µµ±¸°¡ Àý½ÇÈ÷ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º Ç÷§ÆûÀÌ ¹æ´ëÇÑ µ¥ÀÌÅÍ ¼¼Æ®¸¦ ºÐ¼®ÇÏ¿© ±Ù°Å¿¡ ±â¹ÝÇÑ ÃßõÀ» ½Ç½Ã°£À¸·Î Á¦°øÇÏ´Â ´É·ÂÀº Á¤¹ÐÀÇÇÐÀ» Çü¼ºÇÏ´Â µ¥ ÀÖ¾î ±× ¿ªÇÒÀ» ÃËÁøÇÏ°í ±Þ¼º±â ¹× ¸¸¼º±â Ä¡·á °ü¸®¿¡ º¯È­¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù.

º´¿ø°ú ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀÌ Å¬¸®´ÏÄà ÀÎÅÚ¸®Àü½º ¼Ö·ç¼ÇÀ» ºü¸£°Ô µµÀÔÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

º´¿ø ¹× ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üÀÇ Å¬¸®´ÏÄà ÀÎÅÚ¸®Àü½º¿¡ ´ëÇÑ ¼ö¿ä´Â ÁÖ·Î ÀÓ»ó ¿öÅ©ÇÃ·Î¿ì °£¼ÒÈ­, ºñ¿ë Àý°¨ ¹× ÀÇ·á ¼­ºñ½º ǰÁú Çâ»ó¿¡ ´ëÇÑ Çʿ伺¿¡ ÀÇÇØ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇコÄɾ º¼·ý ±â¹Ý¿¡¼­ °¡Ä¡ ±â¹ÝÀ¸·Î ÀüȯµÊ¿¡ µû¶ó º¹ÀâÇÑ ÀÇ»ç°áÁ¤°ú ¿¹Ãø ºÐ¼®À» Áö¿øÇÒ ¼ö ÀÖ´Â º¸´Ù °íµµÈ­µÇ°í ÅëÇÕµÈ Ç÷§ÆûÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º ½Ã½ºÅÛÀº ÇöÀç Áø´Ü Á¤È®µµ Çâ»ó, ȯÀÚ °á°ú ¸ð´ÏÅ͸µ, °í±Þ °èÃþÈ­ ¸ðµ¨À» ÅëÇÑ °íÀ§Ç豺 ȯÀÚ ½Äº°À» ÅëÇÑ Á¶±â °³ÀÔÀ» ÃËÁøÇϱâ À§ÇØ µµÀԵǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º´¿øÀº ÀÌ·¯ÇÑ ½Ã½ºÅÛÀ» Ȱ¿ëÇÏ¿© Àη ¹èÄ¡ºÎÅÍ º´»ó °ü¸®±îÁö ÀÚ¿ø Ȱ¿ëÀ» ÃÖÀûÈ­ÇÏ°í ¾÷¹« È¿À²¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀº Á¡Á¡ ´õ ¸¹Àº ±ÔÁ¦¸¦ ¹Þ°í Àֱ⠶§¹®¿¡ Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º´Â ¹®¼­È­, ÄÚµù, ÀÓ»ó Áöħ Áؼö¸¦ ÀÚµ¿È­ÇÏ¿© ±ÔÁ¤ Áؼö¸¦ µ½°í ÀÖ½À´Ï´Ù. ¸¹Àº ´ëÇк´¿ø°ú ´ëÇü º´¿ø ½Ã½ºÅÛÀº EHR Ç÷§Æû¿¡ ÀÎÅÚ¸®Àü½º ÅøÀ» ÅëÇÕÇÏ¿© Áø·á ½ÃÁ¡¿¡ ÅëÂû·ÂÀ» Á¦°øÇϰí, ¿À·ù¸¦ ÁÙÀ̰í, Áø´Ü¿¡ °É¸®´Â ½Ã°£À» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÃøÁ¤ °¡´ÉÇÑ °á°ú¸¦ ÀÔÁõÇØ¾ß ÇÑ´Ù´Â ¾Ð¹Ú°¨ÀÌ ÀÇ·á ±â°üÀÌ Àü·«Àû Â÷º°È­ ¿ä¼Ò·Î Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º¸¦ µµÀÔÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ½Ç½Ã°£ ¸ð´ÏÅ͸µ µµ±¸¿Í AI ±â¹Ý ºÐ¼®ÀÇ ÅëÇÕÀº Ä¡·á °èȹÀÇ Àû½Ã¼º°ú Á¤È®¼ºÀ» ³ôÀÌ´Â µ¿½Ã¿¡ ´ÙÁ÷Á¾ ÆÀ °£ÀÇ ¿øÈ°ÇÑ Ä¿¹Â´ÏÄÉÀ̼ÇÀ» ÃËÁøÇÕ´Ï´Ù. À̴ ƯÈ÷ ÁßȯÀÚ½Ç(ICU), ÀÀ±Þ½Ç, Á¾¾ç³»°ú µî ÇÑ½Ã¶óµµ »¡¸® ÀÇ»ç°áÁ¤À» ³»·Á¾ß ÇÏ´Â »óȲ¿¡¼­ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ ½ÃÀå¿¡¼­´Â ÇコÄɾî IT º¥´õ¿Í º´¿øÀÌ Çù·ÂÇÏ¿© ƯÁ¤ ÀÇ·á±â°üÀÇ ´ÏÁî¿¡ ¸Â´Â Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º ½Ã½ºÅÛÀ» °øµ¿ °³¹ßÇÏ´Â ¿òÁ÷ÀÓÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í µ¥ÀÌÅÍ º¸¾È¿¡ ´ëÇÑ ¿ì·Á´Â ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀΰ¡, ¾Æ´Ï¸é °¡¼ÓÈ­ÇÒ °ÍÀΰ¡?

Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º´Â Çõ½ÅÀûÀÎ ÀÌÁ¡À» Á¦°øÇÏÁö¸¸, ±× ¼ºÀå ±ËÀûÀº ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, µ¥ÀÌÅÍ °Å¹ö³Í½º, »çÀ̹ö º¸¾ÈÀÇ °úÁ¦¿¡ µû¶ó Å©°Ô Á¿ìµË´Ï´Ù. ¹Ì±¹ FDA, À¯·´ EMA¿Í °°Àº ±ÔÁ¦ ±â°üÀº ÀÓ»ó ÀÇ»ç °áÁ¤¿¡ ÀÖ¾î AI¿Í ¾Ö³Î¸®Æ½½ºÀÇ È°¿ë¿¡ ´ëÇÑ ±âÁØÀ» Á¤ÀÇÇϱâ À§ÇØ Àû±ØÀûÀ¸·Î ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦´Â ÇÊ¿äÇÏÁö¸¸, ¼ÒÇÁÆ®¿þ¾î °³¹ß ÁÖ±â¿Í ÄÄÇöóÀ̾𽺠ÇÁ·ÎÅäÄÝ¿¡ º¹À⼺À» °¡Á®¿É´Ï´Ù. ÇÑÆíÀ¸·Î ¾ö°ÝÇÑ ±ÔÁ¦´Â »õ·Î¿î ¼Ö·ç¼ÇÀÇ ½ÂÀΰú ÅëÇÕÀ» Áö¿¬½Ãų ¼ö ÀÖÀ¸¸ç, ´Ù¸¥ ÇÑÆíÀ¸·Î´Â È®Àå °¡´ÉÇϰí À±¸®ÀûÀÎ Çõ½ÅÀ» À§ÇÑ ±¸Á¶È­µÈ °æ·Î¸¦ Á¦°øÇÕ´Ï´Ù. ƯÈ÷ HIPAA, GDPR(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤), ¿©·¯ ±¹°¡ÀÇ ÀÇ·áÁ¤º¸¹ý°ú °°Àº ÇÁ·¹ÀÓ¿öÅ©¿¡¼­ ȯÀÚ µ¥ÀÌÅÍÀÇ ÇÁ¶óÀ̹ö½Ã°¡ Á¡Á¡ ´õ °­Á¶µÇ°í Àֱ⠶§¹®¿¡ ÀÓ»óÁ¤º¸ Ç÷§ÆûÀº °­·ÂÇÑ ¾Ïȣȭ, À͸íÈ­, °¨»ç °¡´ÉÇÑ ±â´ÉÀ» ³»ÀåÇØ¾ß ÇÕ´Ï´Ù. ÀÓ»ó µ¥ÀÌÅÍ´Â ±â¹Ð¼ºÀÌ ³ô°í, º´¿ø°ú ÀÇ·á ½Ã½ºÅÛÀ» ´ë»óÀ¸·Î ÇÑ »çÀ̹ö °ø°ÝÀÌ ºó¹øÇÏ°Ô ¹ß»ýÇϱ⠶§¹®¿¡ º¸¾ÈÀº ¿©ÀüÈ÷ ÇコÄɾî Á¶Á÷ÀÇ °¡Àå Å« °ü½É»çÀÔ´Ï´Ù. ÀÌ¿¡ ´ëÀÀÇϱâ À§ÇØ ¸¹Àº º¥´õµéÀÌ °íµµÀÇ º¸¾È °èÃþ°ú ½Ç½Ã°£ ¸ð´ÏÅ͸µ ±â´ÉÀ» °®Ãá Ç÷§ÆûÀ» °­È­ÇÏ¿© ±ÔÁ¦ Áؼö¿Í »ç¿ëÀÚ ½Å·Ú¸¦ È®º¸Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ Ŭ¶ó¿ìµå ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ±âȸ¿Í À§ÇèÀÌ µ¿½Ã¿¡ ¹ß»ýÇÕ´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀº È®À强, ½Ç½Ã°£ ¾×¼¼½º, ºñ¿ë È¿À²¼ºÀ» Çâ»ó½ÃŰ´Â µ¿½Ã¿¡ ¾ö°ÝÇÑ º¸¾È ÇÁ·ÎÅäÄÝÀ» ¿ä±¸ÇÕ´Ï´Ù. Èï¹Ì·Ó°Ôµµ, Á¤ºÎ¿Í º¸°ÇºÎ´Â µðÁöÅÐ Çコ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÀÚ±ÝÀ» Áö¿øÇϰí, Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º¸¦ Áö¿øÇÏ´Â ¾ÈÀüÇÏ°í ±ÔÁ¤À» ÁؼöÇÏ´Â ÀÎÇÁ¶ó °³¹ß¿¡ ¿¹»êÀ» ¹èÁ¤Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅõÀÚ´Â Àå±âÀûÀ¸·Î ½ÃÀå È®´ë·Î À̾îÁ® º¸´Ù Ç¥ÁØÈ­µÈ ¾ÈÀüÇÑ »ýŰ迡 ±â¿©Çϰí ÀÖ½À´Ï´Ù.

»ê¾÷°ú Áö¿ªÀ» ÃÊ¿ùÇÑ Å¬¸®´ÏÄà ÀÎÅÚ¸®Àü½º ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ÀÇ·á ¼­ºñ½º Á¦°ø ¸ðµ¨ÀÇ º¯È­, ¼ÒºñÀÚ ±â´ëÄ¡ÀÇ ÁøÈ­, ºÎ¹® °£ Çù·Â °­È­ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÇコÄɾî IT ºÐ¾ß¿¡¼­ ÀΰøÁö´É, µö·¯´×, ºòµ¥ÀÌÅÍ ºÐ¼®ÀÇ ±Þ¼ÓÇÑ µµÀÔÀº Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º µµ±¸ÀÇ ¹ø¿µÀ» À§ÇÑ °­·ÂÇÑ ±â¹ÝÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÚ¿¬¾î ó¸®ÀÇ ¹ßÀüÀ¸·Î ÀÇ»ç ¸Þ¸ð, ¹æ»ç¼± º¸°í¼­, ÀÓ»ó ±â·Ï°ú °°Àº ºñÁ¤Çü µ¥ÀÌÅÍ¿¡¼­ ´õ ³ªÀº ÅëÂû·ÂÀ» ÃßÃâÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ¿Í ÇÔ²² »óÈ£¿î¿ë °¡´ÉÇÑ Ç÷§Æû°ú ÀÇ·áÁ¤º¸±³·ù(HIE)ÀÇ µîÀåÀ¸·Î ºÎ¼­¿Í ±â°üÀ» ³Ñ³ªµå´Â ¿øÈ°ÇÑ µ¥ÀÌÅÍ °øÀ¯°¡ °¡´ÉÇØÁö¸é¼­ ºÐ¼® µµ±¸ÀÇ À¯¿ë¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ »ç¿ëÀÚ Ãø¸é¿¡¼­´Â ¿Ü·¡Áø·á¼¾ÅÍ, Áø´Ü°Ë»ç½Ç, Àü¹® Ŭ¸®´ÐÀÇ È®´ë·Î ÀÎÇØ ƯÁ¤ ÀÌ¿ë »ç·Ê¿¡ ¸Â°Ô È®Àå °¡´ÉÇÑ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼±Áø±¹°ú °³¹ßµµ»ó±¹À» ¸··ÐÇÏ°í ¸¸¼ºÁúȯÀÇ È®»ê°ú Àα¸ÀÇ °í·ÉÈ­°¡ ÁøÇàµÊ¿¡ µû¶ó µ¥ÀÌÅÍ ±â¹ÝÀÇ Àû±ØÀûÀÎ Äɾî Á¦°øÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¼ÒºñÀÚ Çൿµµ º¯È­Çϰí ÀÖÀ¸¸ç, ȯÀÚµéÀº º¸´Ù °³ÀÎÈ­µÇ°í, Åõ¸íÇϰí, ½Ã±âÀûÀýÇÑ Áø·á¸¦ ±â´ëÇÕ´Ï´Ù. Á¦¾àȸ»ç´Â Ŭ¸®´ÏÄà ÀÎÅÚ¸®Àü½º¸¦ ½ÇÁ¦ Áõ°Å »ý¼º, ÀÓ»ó½ÃÇè ÃÖÀûÈ­, ÀǾàǰ ¾ÈÀü¼º ¸ð´ÏÅ͸µ¿¡ Á¡Á¡ ´õ ¸¹ÀÌ È°¿ëÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ´õ ¸¹Àº ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, º¥Ã³Ä³ÇÇÅаú ¹Î°ü ÆÄÆ®³Ê½ÊÀ» ÅëÇÑ ÀÚ±Ý Á¶´Þ°ú ´õºÒ¾î, ±â¼ú ´ë±â¾÷°ú ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿ÍÀÇ Àü·«Àû Çù¾÷Àº Çõ½Å Áֱ⸦ °¡¼ÓÈ­ÇÏ°í ½ÃÀå ħÅõ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áý¾àÀûÀÎ ¿ä¼ÒµéÀº ½ÃÀåÀ» ¹ßÀü½Ãų »Ó¸¸ ¾Æ´Ï¶ó ÇコÄɾîÀÇ ÆÐ·¯´ÙÀÓÀ» Á¡Á¡ ´õ ¿¹Ãø, ¿¹¹æ, Á¤¹Ð ÁöÇâÀûÀÎ °ÍÀ¸·Î À籸¼ºÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° (¼±Çü Àü±â±â°è ¾×Ãß¿¡ÀÌÅÍ, ÇÉ Á¦¾î ¾×Ãß¿¡ÀÌÅÍ, ÆßÇÁ ¸ðÅÍ, ÃßÁø ¸ðÅÍ); Çü»ó (À¯¼±Çü Á¤±Ô ½ºÅ¸ÀÏ Çü»ó, Ãþ·ù À¯Ã¼ Çü»ó, ¾î·ÚÇü Çü»ó, ´ÙÁß ¼±Ã¼ Â÷·® Çü»ó); Àû¿ë ºÐ¾ß (¼ö»ö ¹× ±¸Á¶ ÀÛ¾÷ Àû¿ë, ÇØ¾çÇÐ Àû¿ë, ¼®À¯ ¹× °¡½º Àû¿ë, °í°íÇÐ ¹× Ž»ç Àû¿ë, ±º»ç ¹× ¹æÀ§ Àû¿ë, ȯ°æ º¸È£ ¹× ¸ð´ÏÅ͸µ Àû¿ë)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Clinical Intelligence Market to Reach US$3.6 Billion by 2030

The global market for Clinical Intelligence estimated at US$1.6 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 14.8% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 16.5% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Hardware Component segment is estimated at 11.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$408.8 Million While China is Forecast to Grow at 13.8% CAGR

The Clinical Intelligence market in the U.S. is estimated at US$408.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$548.0 Million by the year 2030 trailing a CAGR of 13.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.8% and 12.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Global Clinical Intelligence Market - Key Trends & Drivers Summarized

How Is Clinical Intelligence Transforming Healthcare Decision-Making Worldwide?

The global clinical intelligence market is undergoing a radical transformation, becoming an integral pillar of the evolving healthcare landscape. As healthcare systems around the world grapple with data overload, rising patient volumes, and growing demand for personalized care, clinical intelligence is emerging as a vital tool to translate raw data into actionable insights. This technology harnesses big data analytics, machine learning algorithms, natural language processing, and real-time patient data integration to provide clinical decision support, improve patient outcomes, and reduce operational inefficiencies. Its applications extend from predictive modeling and risk stratification to population health management and clinical workflow optimization. Governments and health agencies in regions such as North America, Europe, and Asia-Pacific are increasingly integrating clinical intelligence into public health initiatives to enhance value-based care delivery. Notably, the rapid digitization of healthcare records, with electronic health records (EHR) and interoperable systems gaining traction, is significantly accelerating adoption. Moreover, the focus on patient-centric models has created a pressing need for advanced tools that can bridge the information gap between diagnosis and treatment pathways. The ability of clinical intelligence platforms to analyze vast datasets and deliver real-time, evidence-based recommendations is propelling their role in shaping precision medicine, thus transforming both acute and chronic care management.

Why Are Hospitals and Healthcare Providers Rapidly Adopting Clinical Intelligence Solutions?

The demand for clinical intelligence among hospitals and healthcare providers is escalating, primarily driven by the need to streamline clinical workflows, reduce costs, and enhance care quality. As healthcare institutions shift from volume-based to value-based care, they require more advanced, integrated platforms capable of supporting complex decision-making and predictive analytics. Clinical intelligence systems are now being deployed to improve diagnostic accuracy, monitor patient outcomes, and facilitate early intervention by identifying high-risk patients through advanced stratification models. Hospitals are also utilizing these systems to optimize resource utilization, from staffing to bed management, thereby improving operational efficiency. Furthermore, with healthcare providers under increasing regulatory scrutiny, clinical intelligence aids in compliance by automating documentation, coding, and adherence to clinical guidelines. Many academic medical centers and large hospital systems are embedding intelligence tools into EHR platforms to deliver point-of-care insights, reduce errors, and shorten the diagnostic journey. Additionally, the pressure to demonstrate measurable outcomes is pushing institutions to adopt clinical intelligence as a strategic differentiator. The integration of real-time monitoring tools with AI-driven analytics is enhancing the timeliness and accuracy of treatment plans, while facilitating seamless communication across multidisciplinary teams. This is particularly crucial in intensive care units (ICUs), emergency departments, and oncology settings where time-sensitive decisions are critical. The market is witnessing a surge in collaborations between healthcare IT vendors and hospitals to co-develop tailored clinical intelligence systems that can cater to specific institutional needs.

Could Regulatory Frameworks and Data Security Concerns Hinder or Accelerate Market Growth?

While clinical intelligence offers transformative benefits, its growth trajectory is shaped significantly by regulatory frameworks, data governance, and cybersecurity challenges. Regulatory bodies such as the FDA in the United States and the EMA in Europe are actively working to define standards for the deployment of AI and analytics in clinical decision-making. These regulations, although necessary, introduce complexities in software development cycles and compliance protocols. On the one hand, stringent regulations may delay the approval and integration of new solutions; on the other hand, they offer a structured pathway for scalable and ethical innovation. The increasing emphasis on patient data privacy, especially under frameworks like HIPAA, GDPR, and various national health information acts, requires that clinical intelligence platforms incorporate robust encryption, anonymization, and auditability features. Security remains a top concern for healthcare organizations due to the sensitive nature of clinical data and the growing frequency of cyberattacks targeting hospitals and health systems. In response, many vendors are enhancing their platforms with advanced security layers and real-time monitoring to ensure regulatory compliance and instill user trust. At the same time, the growing reliance on cloud infrastructure introduces both opportunities and risks. While cloud-based platforms improve scalability, real-time access, and cost-effectiveness, they also demand rigorous security protocols. Interestingly, governments and health ministries are increasingly funding digital health initiatives and allocating budgets toward the development of secure, compliant infrastructure that supports clinical intelligence. These investments are contributing to a more standardized and secure ecosystem that is conducive to long-term market expansion.

What Is Fueling the Rise of the Clinical Intelligence Market Across Industries and Geographies?

The growth in the clinical intelligence market is driven by several factors rooted in technological advancements, shifting healthcare delivery models, evolving consumer expectations, and increased cross-sector collaboration. The rapid adoption of artificial intelligence, deep learning, and big data analytics in healthcare IT is creating a strong foundation for clinical intelligence tools to flourish. Advances in natural language processing are enabling better extraction of insights from unstructured data such as physician notes, radiology reports, and clinical transcripts. In parallel, the rise of interoperable platforms and Health Information Exchanges (HIEs) is allowing seamless data sharing across departments and institutions, thereby enhancing the utility of analytics tools. On the end-user front, the expanding footprint of ambulatory care centers, diagnostic labs, and specialized clinics is boosting demand for scalable clinical intelligence systems tailored for specific use cases. Furthermore, the increasing prevalence of chronic diseases, coupled with aging populations in developed and developing nations alike, is necessitating proactive, data-driven approaches to care delivery. Consumer behavior is also shifting, with patients expecting more personalized, transparent, and timely care - expectations that clinical intelligence is uniquely positioned to meet. Pharmaceutical companies are increasingly leveraging clinical intelligence for real-world evidence generation, clinical trial optimization, and drug safety monitoring, creating additional demand streams. Finally, strategic collaborations between tech giants and healthcare providers, alongside funding from venture capital and public-private partnerships, are facilitating faster innovation cycles and wider market penetration. These converging factors are not only propelling the market forward but also reshaping the healthcare paradigm toward one that is increasingly predictive, preventive, and precision-oriented.

SCOPE OF STUDY:

The report analyzes the Clinical Intelligence market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Software Component, Hardware Component, Services Component); Type (Population Health Management, Retrospective Performance Management & Predictive Analytics, Clinical Benchmarking, Clinical Decision Support System, Other Types); Application (Revenue Cycle Management Claims Application, Supply Chain Application, Fraud Application, Other Applications); End-Use (Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â